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Abstract 
This study was designed to evaluate whether primary care physicians in Spain accurately diagnose the metabolic 
syndrome in hypertensive patients, to define the profile and management of these patients in clinical practice, and to 
ascertain the level of blood pressure and low-density lipoprotein cholesterol control. Data were analyzed from a 
cross-sectional survey involving 12,954 patients with hypertension (Prevención Cardiovascular en España en 
Atención Primaria: Intervención Sobre el Colesterol en Hipertensión [PRESCOT] study), wherein 52% of the cohort 
fulfilled the National Cholesterol Education Program-Adult Treatment Panel criteria for the metabolic syndrome. The 
majority of patients (54.6%) had 3 risk factors, 32.4% had 4, and 13% had 5 risk factors. Physician diagnosis of the 
metabolic syndrome was poor, with 43.7% of physicians missing the diagnosis and 12.9% wrongly diagnosing the 
metabolic syndrome. Blood pressure and low-density lipoprotein cholesterol control rates were very low, with only 
4.7% of metabolic syndrome patients achieving control for both blood pressure and low-density lipoprotein 
cholesterol vs 13.5% for non-metabolic syndrome patients (P<.0001). These findings demonstrate that the metabolic 
syndrome is common in patients with hypertension and that it is generally poorly diagnosed and treated by primary 
care physicians. 
The metabolic syndrome (MetS) is characterized by an array of cardiovascular risk factors that may be 
predictive of longer-term disease sequelae in certain individuals. The syndrome is associated with insulin 
resistance and hyperglycemia and coincides with an increased risk of developing type 2 diabetes and 
cardiovascular disease.1–5 Although Reaven6 described the syndrome in the late 1980s, a precise 
definition and the clinical importance of MetS are still evolving. In the United States, the Third Report of 
the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and 
Treatment of High Blood Cholesterol in Adults (ATP III)7 has provided a relatively simple definition of 
MetS. NCEP-ATP III criteria are widely used in clinical practice, and they facilitate an easy identification 
of the syndrome with uncomplicated criteria that can be applied in the most basic health care setting. 
Recently, the International Diabetes Federation (IDF) proposed a definition that emphasizes the 
importance of abdominal obesity and lowers the threshold for several parameters such as waist 
circumference, blood pressure (BP), and fasting plasma glucose.8 
As diabetes and obesity in Western countries are increasing, almost to epidemic proportions, not 
surprisingly the prevalence of MetS is progressively growing.9 Without intervention this will almost 
certainly result in an increase in cardiovascular morbidity and place a greater burden on Western 
society.10,11 
Although MetS is associated with cardiovascular disease, the risk is not homogeneous and may vary 
according to age, sex, and severity.12,13 Patients with hypertension and MetS represent a particularly high-
risk group, not only because of the higher prevalence of target organ damage,14 but also because of the 
increased incidence of cardiovascular complications observed in this population.12,15 The presence of 
MetS in hypertensive patients acquires greater clinical relevance and, to improve prognosis, it is 
important to be able to accurately diagnose MetS, to better understand the long-term impact, and to 
reduce the number and severity of risk factors. BP and low-density lipoprotein cholesterol (LDL-C) are 
established risk factors that are strongly associated with cardiovascular morbidity and mortality, and 
longer-term control of these will likely significantly improve the survival of MetS patients.16 
MetS has been associated with an increased risk for cardiovascular disease in a number of pivotal 
trials, including community-based populations, and in primary preventive settings.1 Studies involving 
large numbers of patients with hypertension and MetS treated in Spanish general practice facilities are not 
so common. Furthermore, few data are available regarding the ability of primary care physicians to 
accurately diagnose MetS. The goals of this general practice study undertaken in Spain were to: 
 
 •Determine the prevalence of MetS according to the NCEP-ATP III definition; 
 •Determine accuracy in physician diagnosis of MetS; 
 •Determine the demographics of and medications used in patients with MetS compared with 
those without MetS; and 
 •Compare control rates of BP and lipids in patients with and without MetS. 
Patients and Methods 
Study Population.  
The study population involved patients with hypertension included in the Prevención Cardiovascular 
en España en Atención Primaria: Intervención Sobre el Colesterol en Hipertensión (PRESCOT) cross-
sectional epidemiologic survey. The aim was to determine the clinical profile and associated risk factors, 
including MetS, in a population of patients with hypertension attending general practice clinics across 
Spain. Approximately 2000 primary care physicians participated in the study, which was performed 
during the first quarter of 2004. Each investigator was asked to include the first 6 patients with 
hypertension who attended their outpatient clinic. Inclusion criteria were age 18 years and older, man or 
woman, hypertension (systolic BP >140 mm Hg and/or diastolic BP >90 mm Hg or receiving 
antihypertensive treatment), and an available blood test with a complete lipid profile within the past 6 
months. To best reflect clinical practice in Spain, no specific exclusion criteria were defined. 
Methodology and Data Collection.  
Seated BP was measured after 5 minutes of resting. Two measurements were taken and the mean was 
recorded. BP was considered to be well controlled using the guidelines of the European Society of 
Hypertension (<140/90 mm Hg for the general population and <130/80 mm Hg for diabetic patients).15 
Patients were classified as dyslipidemic when they had a confirmed diagnosis of an impaired lipid 
profile (hypercholesterolemia, hypertriglyceridemia, or mixed hyperlipidemia) according to NCEP-ATP 
III or were receiving lipid-lowering therapy. 
Coronary risk stratification was performed using the NCEP-ATP III classification. 7 High-risk patients 
were those with coronary disease or a risk equivalent (10-year coronary risk >20%), medium-risk patients 
were those with 2 or more risk factors (10-year coronary risk 10%–20%), and low-risk patients were 
those with 1 or no cardiovascular risk factors (10-year coronary risk <10%). Coronary risk equivalents 
included peripheral arterial disease, abdominal aortic aneurysm, carotid disease, and diabetes. Risk 
factors included smoking, high BP, decreased levels of high-density lipoprotein cholesterol (HDL-C) 
(<40 mg/dL), family history of premature coronary disease (first-degree relatives younger than 55 years 
in men and younger than 65 years in women), and age (45 or older in men and 55 and older in women).7 
LDL-C control was thus defined in relation to the above risk categories as established by NCEP-ATP III 
guidelines: LDL-C <100 mg/dL for the high-risk group, <130 mg/dL for the medium-risk group, and 
<160 mg/dL for the low-risk group. 
MetS was diagnosed using NCEP-ATP III criteria requiring the presence of 3 or more of the 
following: abdominal obesity (waist circumference >102/88 cm or >40/35 inches for men/women); 
triglycerides ≥150 mg/dL; HDL-C <40/50 mg/dL (men/women); fasting glucose ≥110 mg/dL; or BP 
≥130/85 mm Hg.7 Waist circumference was measured at the midway point between the iliac crest and the 
costal margin. NCEP-ATP III criteria were used to define MetS because of their ease in applying in 
primary care, which has caused this definition to be the most utilized by general practitioners in Spain. 
The physicians completed a specific individual case report form with all the collected clinical and analytic 
data. They were asked to identify the presence of MetS according ATP III criteria, and the diagnosis was 
specifically recorded in the case report form. To facilitate the physicians' task, a sheet with the ATP III 
diagnostic criteria was included in the study documentation. A post hoc analysis was performed using the 
IDF criteria.8 
To evaluate whether primary care physicians correctly identified MetS, their diagnosis was compared 
with an independent control assessment using patient data stored on a central database. 
Statistical Analyses.  
Various statistical tests were performed depending on the nature of variables being compared. The 
chi-square test was used to analyze the relationship between categoric variables; however, when >20% of 
the cells had an expected frequency lower than 5, the Fisher exact test was employed. Comparison of 
continuous variables between groups was performed using the Student t test. Database design was 
subjected to internal consistency rules and ranges to control inconsistencies/inaccuracies in the collection 
and tabulation of data (SPSS version 11.0.1; SPSS Inc, Cary, NC). 
Results 
The PRESCOT survey enrolled a total of 15,707 patients, of which 12,954 (82.5%) were finally 
included in the analysis after excluding those who did not comply with the selection criteria and/or whose 
case report forms were incomplete and/or inconsistent. Of the 12,954 patients included in the survey, 
5866 (52%) fulfilled NCEP-ATP III diagnostic criteria for MetS. Of these, 54.6% had the minimum of 3 
MetS risk factors, 32.4% had 4 risk factors, and 13% had 5 risk factors. Interestingly, if the newer IDF 
classification8 was applied, the prevalence of MetS in our hypertensive population would have risen from 
52% to 75.5%. 
Table I details the baseline characteristics of the overall study population subdivided into patients with 
MetS and patients without MetS. All risk factors for cardiovascular disease relating to BP control and 
hyperlipidemia were significantly worse in the MetS group (higher systolic and diastolic BP, total 
cholesterol, LDL-C and triglycerides, and lower HDL-C levels). Interestingly, there were more women 
than men in the MetS group (56.1% vs 43.9%, respectively; P<.0001). Excluding hypertension, the most 
common components of MetS were abdominal obesity (as measured by waist circumference; 50.5% of 
cases) and increased triglyceride levels (49.8% of cases). There were some significant sex-related 
distribution differences in the patients with MetS (Table II), with more women than men presenting with 
abdominal obesity (59.6%vs 41.4%, respectively; P<.0001) and low HDL-C levels (40.3% vs 18.7%, 
respectively; P<.0001) and more men than women presenting with hypertriglyceridemia (56.7% vs 
43.4%, respectively; P<.0001). 
Table I.  Characteristics of Patients With Hypertension in the PRESCOT Trial by Presence or Absence of the Metabolic Syndrome 
(MetS) 
 
Demographic Data  
 
Variables Hypertensive Patients With MetS Hypertensive Patients Without MetS  P 
     
Sex, male/female, % 43.9/56.1 55.5/44.5  <.0001* 
Age, y 62.3±10.5 62.1±10.8  .5161† 
BMI, kg/m2 29.6±4.3 27.3±3.7  <.0001† 
Waist circumference, cm 104.9±15.4 93.4±14.3  <.0001† 
SBP, mm Hg 145.8±14.3 142.2±13.8  <.0001† 
DBP, mm Hg 86.0±9.1 83.9±8.9  <.0001† 
Total cholesterol, mg/dL 237.3±40.9 227.3±42.2  <.0001† 
Triglycerides, mg/dL 192.3±92.2 120.1±46.6  <.0001† 
LDL cholesterol, mg/dL 154.2±93.5 144.8±76.0  <.0001† 
HDL cholesterol, mg/dL 47.8±17.0 58.5±16.4  <.0001† 
Fasting plasma glucose, mg/dL 124.4±37.7 96.8±16.7  <.0001† 
     
 
PRESCOT indicates the Prevención Cardiovascular en España en Atención Primaria Intervención Sobre el Colesterol en 
Hipertensión study; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; LDL, low-density 
lipoprotein; and HDL, high-density lipoprotein. *Chi-square test. †Student t test. 
  
Table II.  Prevalence of the Different ATP III Components in Patients With the Metabolic Syndrome 
Risk Factor Total, % Men, % Women, % p* 
     
Hypertension (BP ≥130/85 mm Hg or Rx) 100 100 100 – 
Waist circumference >102 cm for men or >88 cm for women 50.5 41.4 59.6 <.0001 
Triglycerides ≥150 mg/dL 49.8 56.7 43.4 <.0001 
Low HDL cholesterol <40 mg/dL for men or <50 mg/dL for women 29.5 18.7 40.3 <.0001 
Fasting plasma glucose >110 mg/dL 35.6 35.7 35.5 .8079 
     
 
ATP III indicates the third report of the Adult Treatment Panel; BP, blood pressure; Rx, receiving antihypertensive treatment; and 
HDL, high-density lipoprotein. *Student t test for continuous variables; chi-square test for categoric variables. 
The 98.2% of patients with MetS were taking at least 1 antihypertensive drug; 17.7% were on 
monotherapy and 80.5% were treated with 2 or more drugs. MetS patients were taking significantly more 
antihypertensive medication than those without MetS (45.3% vs 36.6% were on combined therapy, 
respectively; P<.001). The use of angiotensin-converting enzyme inhibitors and angiotensin receptor 
blockers (74.8% vs 67.6%, respectively; P<.001) and statins (43.0% vs 39.1%, respectively; P<.001) was 
more frequent in MetS patients. Table III represents the percentage of antihypertensive and lipid-lowering 
drugs used in patients according to the presence of MetS. 
Table III.  Percentage of Antihypertensive and Lipid-Lowering Drugs Used in Patients According to the Presence of the Metabolic 
Syndrome (MetS) 
Type Of Treatment Hypertensive Patients With MetS, % Hypertensive Patients Without MetS, % 
 
Antihypertensive drugs 
 ACEIs 43.5 39.6 
 Diuretics 38.3 32.8 
 ARBs 32.7 28.7 
 Calcium antagonists 20.3 17.7 
 β-Blockers 12.7 13.0 
 ACEI and ARB 74.8 67.6 
 Other 4 3.5 
Lipid-lowering drugs 
 Statins 43.0 39.1 
 Other 5.8 2.6 
   
 
ACEI indicates angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker. 
The diagnosis concordance between physicians and a control assessment was 56.3% for the presence 
of MetS and 87.1% for the absence of MetS (Figure 1). Crucially, general practitioners did not diagnose 
43.7% of cases of MetS and 12.9% of patients were wrongly diagnosed as having MetS despite not 
meeting NCEP-ATP III criteria. 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Diagnosis of the metabolic syndrome (MetS) by primary care physicians 
compared with independent assessment. 
Findings with regard to BP and LDL-C control are presented in Figure 2. BP was controlled in fewer 
patients with MetS compared with those without MetS (17.2% vs 33.6%, respectively; P<.001). Systolic 
BP was controlled in 20.7% of MetS patients and in 37.2% of non-MetS patients (P<.0001), while 
diastolic BP was controlled in 39.0% vs 63.7% (P<.0001), respectively. Similarly, LDL-C control was 
worse in MetS patients than in patients without MetS (17.2% vs 35.7%, respectively; P<.0001). As 
expected, the degree of control of BP and LDL-C combined was also lower in patients with MetS (4.7% 
vs 13.5%; P<.0001). 
 
 
 
Figure 2. Degree of blood pressure and low-density lipoprotein cholesterol (LDL-C) 
control in hypertensive patients according to the presence of the metabolic syndrome 
(MetS). 
Among the patients with MetS, the BP and LDL-C controls were worse in the subgroup of MetS 
patients with diabetes compared with nondiabetics (Table IV). BP was controlled in 23.0% of MetS 
patients without diabetes and in 9.5% of MetS patients with diabetes (P<.001). Similar results were 
observed for LDL-C, control being achieved in 22.2% of MetS nondiabetic patients and 10.5% of MetS 
patients with diabetes (P<.0001). The combined BP and LDL-C control was achieved in 6.3% of non-
diabetic patients with MetS and in only 2.6% of diabetics with MetS (P<.001). 
  
Table IV.  Percentage of Patients With Hypertension and Coexisting Metabolic Syndrome (MetS) (With or Without Diabetes) 
Achieving Control of BP and LDL-C 
Variables 
Hypertensive Patients With MetS and 
Diabetes, % 
Hypertensive Patients With MetS Without 
Diabetes, % 
p* 
    
BP controlled 9.5 23.0 <.0001 
LDL-C controlled 10.5 22.2 <.0001 
Both BP and LDL-C 
controlled 
2.6 6.3 <.0001 
    
 
BP indicates blood pressure; LDL-C, low-density lipoprotein cholesterol.*Student t test for continuous variables; chi-square test for 
categoric variables. 
Discussion 
A number of pivotal studies have been reported in the past 5 years that have investigated the 
prevalence of MetS. One of the pioneering studies in this regard was the third report of the National 
Health and Nutrition Examination Survey (NHANES III) study,17 which randomly selected 8800 
Americans between the ages of 20 and 89 years. The overall prevalence of MetS in this survey was 
21.8%, and studies such as Framingham,18 West of Scotland Coronary Prevention Study (WOSCOPS),19 
the Women's Health Study,20 and other studies carried out in Western countries3–5 have reported similar 
prevalence rates. 
Few studies have been carried out in Spain investigating MetS. Martínez-Larrad and colleagues21 
reported a prevalence of 17% in urban and rural areas using NCEP-ATP III criteria. A prevalence of 
24.4% was observed in the Canary Islands, and the rate increased with age and decreased with 
educational level.22 In a primary care study, Ascaso and colleagues23 found that MetS prevalence was 
48.4% in subjects with abdominal obesity compared with 18.8% in those without abdominal obesity. A 
large study that included more than 19,000 workers recorded a MetS prevalence of 12% (16% in men and 
8% in women).24 Clear geographic differences regarding the distribution of MetS have been detected, and 
these are probably a consequence of different environmental factors such as diet and physical exercise. 
More recently, de la Sierra and associates25 reported a prevalence of 44.6% using NCEP-ATP III criteria 
and 61.7% using IDF criteria in a primary care study in Spain involving 19,039 patients with 
hypertension. The results of our large cross-sectional survey involving hypertensive patients attending 
primary health care centers in Spain demonstrated an even higher prevalence of MetS: 52% using NCEP-
ATP III criteria and 75.5% using IDF criteria. In our series, the presence of MetS was more frequent in 
women (56.1% vs 43.9% for men; P<.0001). It should be taken into account that this study was carried 
out in Spanish primary care; therefore, these results could somehow differ in other sites and may not be 
generalizable to other countries with different health care delivery. 
It is notable that despite being American, the NCEP-ATP III criteria have been widely accepted in 
Spain. It is probably because NCEP-ATP III criteria are easy to apply, which results in the MetS being 
easily diagnosed in primary care. Although the NCEP-ATP III guidelines define MetS as the presence of 
3 or more diagnostic criteria, the risk is not homogeneous and may vary according to age, sex, and 
severity of MetS.12,13 In the current study, almost half of the MetS patients (45.5%) had 4 or 5 diagnostic 
criteria, which is indicative of high cardiovascular risk.12 Furthermore, this study was performed in a 
hypertensive cohort, which, in itself, confers added risk. Therefore, it is not surprising that a higher 
prevalence of MetS was detected in this study compared with general population studies and is more in 
line with findings from trials involving patients with diabetes or heart disease. For example, a prevalence 
of 77% was noted in a study involving 318 type 2 diabetics26 and a rate of 41.1% in patients with heart 
disease.27 
Japanese researchers reported a positive correlation between MetS prevalence and BP in a study 
involving 506 untreated hypertensive patients.28 Patients were divided into 3 groups according to the 
Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of 
High Blood Pressure (JNC 7) classification and the prevalence of MetS was 9.9% in normotensive 
subjects, 19.2% in prehypertensive patients, and 35.5% in the hypertensive subjects. A positive 
correlation between insulin resistance and BP was also documented, and the authors noted that the higher 
the BP, the greater the number of risk factors for MetS. A somewhat higher prevalence of 37.6% for MetS 
in prehypertensive patients was recently reported in the Trial for Preventing Hypertension (TROPHY) 
substudy.29 With regard to MetS prevalence, our study confirms the finding of Ford30 who reported that 
the rate is significantly higher when IDF criteria are used. 
Evaluation of the quality of diagnosis of MetS in the current trial showed that physician diagnosis of 
MetS was generally poor: in 43.7% of cases they missed the diagnosis and in 12.9% they wrongly 
diagnosed MetS when diagnostic criteria were not met. These data highlight the need for continuous 
medical education to improve the management of this syndrome in general practice. Previous studies had 
noted an underestimation of the cardiovascular risk in this setting.31,32 Thus, in the Estratificación del 
Riesgo Cardiovascular en Hipertensión en Atención Primaria e Impacto Sobre el Tratamiento 
Antihipertensivo (DIORISC) study,31 which included 9374 hypertensive patients managed in primary 
care, 61% of patients belonged to a high or very high-risk group, yet physicians only identified 39% of 
these patients as being at high or very high risk (P<.0001).31 
There is now a body of evidence demonstrating that MetS increases cardiovascular morbidity and 
mortality, reinforcing the importance of optimizing management of these patients and achieving adequate 
control of risk factors.16 Furthermore, in hypertensive patients with MetS, cardiovascular morbidity and 
mortality are significantly higher and so the relative risk is compounded. Schillaci and colleagues12 
observed that hypertensive patients with MetS had double the number of cardiovascular events compared 
with patients without MetS. They also noted that the greater the number of MetS risk factors, the worse 
the prognosis. 
The results of the current study provide an insight into the status of the treatment of patients with 
hypertension and coexisting MetS in general practice and highlight some important concerns regarding 
the management of cardiovascular risk. Indeed, the overall control of hypertension and dyslipidemia was 
relatively poor in this cohort. The proportion of patients achieving control of both BP and LDL-C was 
low for the total patient population, but it was worse in patients with MetS than in those without MetS 
(4.7% vs 13.5%,respectively; P<.0001) and worse still in hypertensive patients with MetS and diabetes 
(2.6%). These results indicate that in patients with hypertension, management of BP and LDL-C and risk 
factors for cardiovascular disease is generally very poor in Spain. Management is worse in patients with 
coexisting MetS and, interestingly, this occurs despite the fact that patients with MetS were receiving 
more medications to reduce both BP and LDL-C than patients without MetS and were also receiving 
more antihypertensive drugs than was reported in previous studies.31,33 
The cross-sectional design of the study was chosen to best represent real-world clinical practice. 
Consequently, a large population of hypertensive patients was included in the trial with very few patient 
exclusion criteria. This was achieved by consecutive sampling. This methodology has its limitations since 
it reduces the level of control that can be exercised to reduce variation and bias (eg, random sampling and 
“blind” controls). The large number of patients included in the study, however, and the nature of the end 
points being measured, with no comparators under review, minimizes this theoretical limitation. It is 
notable that, since this study was performed in primary care in Spain, the results may not be generalizable 
to other countries with different health care delivery. 
Overall, the study was designed to represent clinical practice, presenting an accurate picture of the 
hypertensive population attending primary care. 
Conclusions 
These data demonstrate the high prevalence of MetS in a hypertensive population attending primary 
care facilities in Spain. More than half of the patients fulfilled NCEP-ACT III criteria for MetS. 
Management of BP and LDL-C, key risk factors for cardiovascular morbidity and mortality, was worse in 
patients with MetS than in those without the syndrome. 
Although interest in MetS has recently increased, it is not always accurately identified. The findings 
of this study show that it is clearly underdiagnosed and undertreated. This highlights the need for ongoing 
medical education to improve the management of this syndrome in general practice, with the goal of 
aggressively reducing cardiovascular risk. 
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